HCW Biologics Inc. (HCWB) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies to treat age-related diseases by targeting chronic inflammation ("inflammaging"). The company has no commercial product sales; revenue is derived exclusively from a license and supply agreement with Wugen, Inc. The filing highlights significant liquidity challenges, substantial legal expenses related to a recent arbitration settlement, and a "substantial doubt" regarding the company's ability to continue as a going concern without additional financing.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenues | $426,423 | $853,102 | $2,171,988 | $1,517,792 |
| Net Loss | $(3,902,288) | $(4,938,641) | $(26,650,541) | $(14,313,746) |
| Net Loss Per Share | $(0.10) | $(0.14) | $(0.71) | $(0.40) |
| Cash & Equivalents (End of Period) | $998,221 | $11,220,793 | $998,221 | $11,220,793 |
| Total Debt (Short-term + Long-term) | $12,803,280 | $6,304,318 | $12,803,280 | $6,304,318 |
| Accounts Payable | $22,666,107 | $6,167,223 | $22,666,107 | $6,167,223 |
Note: Total Debt includes $6.34M in short-term debt (Cogent Bank loan reclassified due to default risk) and $6.46M in long-term debt (Secured Notes).
Material Changes vs. Prior Period
- Revenue Decline (QoQ): Revenue for the three months ended September 30, 2024, decreased 50% compared to the same period in 2023, driven by reduced supply of clinical materials to Wugen.
- Surge in Legal Expenses: Legal expenses for the nine months ended September 30, 2024, skyrocketed to $15.8 million compared to $4.6 million in the prior year period. This increase is primarily due to costs associated with the arbitration against ImmunityBio/Altor/NantCell, which was settled in July 2024. As of September 30, 2024, approximately $14.4 million of these legal fees remain unpaid and are recorded in Accounts Payable.
- Nonoperating Loss: The company recognized a $1.3 million nonoperating loss in the nine months ended September 30, 2024, resulting from a criminal scheme where funds were misdirected to a fraudulent account. No such loss was recorded in the prior year period.
- Liquidity Deterioration: Cash and cash equivalents dropped from $3.6 million at year-end 2023 to under $1.0 million at September 30, 2024. Net cash used in operating activities was $11.4 million for the nine months ended September 30, 2024.
- Debt Restructuring: The company issued $6.5 million in Senior Secured Notes during the period. Additionally, the $6.5 million Cogent Bank loan was reclassified as short-term debt due to a discretionary default provision triggered by unpaid construction invoices.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the filing date. This is due to cumulative losses, limited cash resources, and significant unpaid liabilities.
- Financing Plan: The company is executing a multi-step financing plan including:
- Issuance of Secured Notes (raised $6.9 million through October 31, 2024).
- Equity financing via an engagement with Maxim Group (announced November 13, 2024).
- Potential licensing of a preclinical molecule with guaranteed minimum payments (expected to close Q4 2024).
- Nasdaq Compliance: The company received notice of non-compliance with Nasdaq listing requirements regarding the market value of listed securities. The deadline to regain compliance is December 16, 2024.
- Legal Settlement: The arbitration with ImmunityBio was settled in July 2024 with no monetary payment required between parties, but the company incurred significant legal fees. The settlement transferred certain oncology rights for the TOBI platform to ImmunityBio, though HCW retains rights for non-oncology indications and specific molecules (HCW9302, HCW9206).
- Internal Control Weaknesses: The company identified material weaknesses in internal controls related to fraud prevention (the $1.3M loss) and accounting for complex debt instruments. A remediation plan is in place, but effectiveness has not yet been fully established.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.0 million cash balance against the $22.7 million in accounts payable and $12.8 million in debt obligations.
- Debt Default Status: Confirm the status of the Cogent Bank loan default and whether the lender has elected to accelerate the debt.
- Legal Fee Payment Plan: Assess the feasibility of the company's plan to negotiate payment terms for the $14.4 million in accrued legal fees.
- Financing Execution: Monitor the progress of the Maxim Group equity financing and the closing of the preclinical molecule license deal.
- Nasdaq Listing: Track the company's ability to meet the December 16, 2024, deadline for Nasdaq compliance or the success of any appeal for an extension.
- Internal Controls: Review future filings for confirmation that the remediation plan for internal control weaknesses has been deemed effective.